Description: WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development, and manufacturing in the People's Republic of China, North America, Europe, and internationally. It also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and material supplier activities. The company has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates. The company was incorporated in 2014 and is headquartered in Wuxi, China.
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 20.8333 |
|---|---|
| Trailing PE: | 27.2917 |
| Price-to-Book MRQ: | 2.8663 |
| Price-to-Sales TTM: | 0.8761 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 12397 |